World First T-Rex Leather™ Product

Summary by AI BETAClose X

BSF Enterprise PLC has unveiled the world's first product made from lab-grown T-Rex Leather™, a luxury handbag, marking a significant milestone for its subsidiary Lab-Grown Leather Ltd. This innovative material, developed using AI and advanced tissue engineering, reconstructs collagen blueprints from extinct protein sequences and cultivates engineered cells without animal slaughter. The company plans to commercialise this technology across luxury fashion, automotive, and performance markets, aiming to capture share in the $60 billion luxury leather and $20 billion bio-based materials markets. The unique handbag will be auctioned later this year.

Disclaimer*

BSF Enterprise PLC
02 April 2026
 

2 April 2026

 

BSF Enterprise PLC

 

Unveiling of World's First T-Rex Leather™ Product

and Commercialisation Roadmap

 

BSF Enterprise PLC (LSE: BSFA; OTCQB: BSFAF), a leader in the field of lab-grown tissues and sustainable biotechnology, is pleased to announce the unveiling of the world's first product made from lab-grown T-Rex Leather™ via its wholly owned subsidiary Lab-Grown Leather Ltd

 

The product, a one-of-a-kind luxury handbag designed by the avant-garde techwear label Enfin Levé, will be debuted today at the Art Zoo Museum in Amsterdam. The unveiling marks a significant milestone for BSF's wholly owned subsidiary, Lab-Grown Leather Ltd., demonstrating the successful application of its proprietary tissue engineering technology to extinct protein sequences.

 

Technological Breakthrough

T-Rex Leather™, an LGL proprietary material forming part of its Elemental Leather™ range, was developed through a unique scientific collaboration between Lab-Grown Leather Ltd., The Organoid Company, with the marketing support of  creative agency VML.

 

●    Reconstruction: Scientists used AI-driven computational modelling to reconstruct complete collagen blueprints from fossilised T.rex sequences. Collagen being the principal structural element preserved in skin during the formation of leather.

●    Cultivation: Using Lab-Grown Leather's Advanced Tissue Engineering Platform (ATEP™), which underpins Elemental Leather™, billions of engineered cells were cultivated to create a uniquely novel material based upon predicted prehistoric genomic information. This innovative platform facilitates the production of  a new class of bio-material, offering unique aesthetics and feel not seen for 68 million years, whilst retaining  structural properties  found in traditional leather but without the need for animal slaughter or synthetic scaffolds.

●    Sustainability: The resulting biomaterial is durable, repairable, biodegradable, and compatible with existing leather finishing techniques.

 

Commercialisation and Market Strategy

While the initial handbag serves as a high-profile proof-of-concept, the Company intends to scale the underlying technology across multiple high-value sectors:

 

●    Luxury Fashion: T-Rex Leather™ will be made commercially available to premium brands and designers for use in luxury accessories.

●    Automotive & Performance: Long-term ambitions include providing high-performance, slaughter-free interiors for the automotive sector and other high-performance material markets.

●    Market Opportunity: The Company is positioning its core product Elemental Leather™ portfolio to capture share in the $60 billion luxury leather market and the $20 billion bio-based materials market.

Upcoming Auction

Following a six-week exhibition at the Art Zoo Museum, the one-of-a-kind T-Rex Leather™ handbag will be sold to the highest bidder. The Company expects the auction to be conducted via a major international auction house later this year. Further details regarding the auction partner and date will be released in due course.

 

Dr Che Connon, commented:

 

"By collaborating with VML and The Organoid Company, we're unlocking the potential to engineer leather from prehistoric species. This venture showcases the power of cell-based technology to create materials that are both innovative and ethically sound, paving the way for commercially attractive improvements in unique character and cost-efficiency".

 

END

 

Engage with the BSF Enterprise management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
website here:

 

https://bsfenterprise.com/about

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

BSF Enterprise PLC

Geoff Baker - Chairman

Che Connon - CEO & Director

 

We encourage all investors to share questions on this announcement via our investor website.

https://bsfenterprise.com/s/a1f22b

Shard Capital (Broker)

Damon Heath

Isabella Pierre

 

(0)20 4530 6926

(0)20 4530 6928

Bowsprit Partners

John Treacy

James Sheehan

 

+44 (0)203 883 4430

ISIN of the Ordinary Shares

is GB00BHNBDQ51.

SEDOL Code is BHNBDQ5.


 

 

 

Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43

 

About BSF Enterprise PLC

BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather (via LGL), cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance alternatives to conventional materials, targeting global markets where provenance, ethics, and performance are increasingly prized by consumers and brands alike.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings